Search results

651 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Quality standards Remove Quality standards filter

Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

In development [GID-HST10032] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

In development [GID-TA10561] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-HST10033] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]

In development [GID-TA10653] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

In development [GID-TA10635] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Type

Technology appraisal guidance

Status

In development
Third molars (impacted) - prophylactic removal [ID898]

In development [GID-TAG525] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]

In development [GID-TA10636] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

Proposed [GID-TA10574] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]

In development [GID-TA10759] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]

In development [GID-TA10398] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

In development [GID-TA10633] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

In development [GID-TA10202] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

In development [GID-TA10537] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]

In development [GID-TA10760] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]

In development [GID-TA10761] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]

Proposed [GID-TA10739] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

In development [GID-TA10577] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Atrial fibrillation - vernakalant [ID454]

In development [GID-TAG428] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]

In development [GID-TA10649] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

In development
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]

In development [GID-TA10756] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610

In development [GID-TA10499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

In development [GID-TA10416] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]

In development [GID-TA10588] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: 15 December 2021

Type

Technology appraisal guidance

Status

In development
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

In development [GID-TA10566] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]

In development [GID-TA10352] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

In development [GID-TA10222] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]

In development [GID-TA10656] Expected publication date: 02 March 2022

Type

Technology appraisal guidance

Status

In development
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

In development [GID-TA10591] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]

Proposed [GID-TA10714] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed